| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007595320 |
| P356 | DOI | 10.1007/S00424-012-1120-0 |
| P8608 | Fatcat ID | release_uadkyhdeuradjl4n2ecj5yaqey |
| P698 | PubMed publication ID | 23463883 |
| P50 | author | Michael Bader | Q37611575 |
| P2860 | cites work | Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule | Q72528938 |
| Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide | Q73086568 | ||
| The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1 | Q73765902 | ||
| Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7) | Q79349822 | ||
| An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats | Q83333697 | ||
| A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase | Q22254730 | ||
| A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 | Q24290169 | ||
| The mas oncogene encodes an angiotensin receptor | Q24298473 | ||
| Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation | Q24311938 | ||
| The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function | Q24633556 | ||
| Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas | Q24680069 | ||
| Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies | Q27648672 | ||
| Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase | Q28115041 | ||
| Angiotensin-converting enzyme 2 is an essential regulator of heart function | Q28205840 | ||
| Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues | Q28583988 | ||
| Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation | Q28584967 | ||
| Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice | Q33319072 | ||
| Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension | Q33639490 | ||
| Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection | Q34049167 | ||
| Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells | Q34115516 | ||
| Enzymatic processing of angiotensin peptides by human glomerular endothelial cells | Q34213566 | ||
| The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension | Q34268946 | ||
| ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. | Q34784864 | ||
| Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases | Q34799585 | ||
| Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice | Q34912847 | ||
| Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. | Q35217354 | ||
| Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice | Q35757097 | ||
| Deficiency of ACE2 in Bone-Marrow-Derived Cells Increases Expression of TNF-α in Adipose Stromal Cells and Augments Glucose Intolerance in Obese C57BL/6 Mice | Q35810634 | ||
| Angiotensin peptides and lung cancer | Q35857462 | ||
| Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury | Q35916066 | ||
| Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. | Q36042466 | ||
| Cardiovascular actions of angiotensin-(1-7). | Q36165955 | ||
| Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart | Q46699250 | ||
| Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology | Q46771630 | ||
| Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice | Q46818973 | ||
| Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism | Q46891673 | ||
| Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats | Q46985305 | ||
| Angiotensin-converting enzyme 2 protects from severe acute lung failure | Q47768368 | ||
| Converting enzyme activity and angiotensin metabolism in the dog brainstem. | Q48120667 | ||
| Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene | Q48451358 | ||
| ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. | Q48491814 | ||
| Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. | Q50518097 | ||
| Angiotensin-(1-7)/Mas axis integrity is required for the expression of object recognition memory. | Q50984005 | ||
| Sex specific behavioural alterations in Mas-deficient mice. | Q51083579 | ||
| Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. | Q51368117 | ||
| Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. | Q51785440 | ||
| Functional rescue of a defective angiotensin II AT1 receptor mutant by the Mas protooncogene. | Q51799424 | ||
| Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. | Q51802034 | ||
| Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. | Q53173814 | ||
| Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. | Q53463683 | ||
| Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. | Q53553738 | ||
| Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. | Q54395386 | ||
| Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway. | Q54705117 | ||
| ACE2–angiotensin-(1–7)–Mas axis in renal ischaemia/reperfusion injury in rats | Q56774944 | ||
| Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor | Q56963259 | ||
| Angiotensin(1-7) Blunts Hypertensive Cardiac Remodeling by a Direct Effect on the Heart | Q56963351 | ||
| Molecular Mechanisms Involved in the Angiotensin-(1-7)/Mas Signaling Pathway in Cardiomyocytes | Q56963383 | ||
| Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice | Q56963485 | ||
| Imprinting of the Murine Mas Protooncogene Is Restricted to Its Antisense RNA | Q56963615 | ||
| Angiotensin-(1–7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats | Q61965141 | ||
| Potentiation of the hypotensive effect of bradykinin by angiotensin-(1–7)-related peptides | Q62124894 | ||
| The emerging role of angiotensin-converting enzyme-2 in the kidney | Q36733547 | ||
| High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs | Q37088267 | ||
| Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis | Q37101896 | ||
| The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice | Q37151662 | ||
| Angiotensin-converting enzyme 2 in the brain: properties and future directions | Q37155907 | ||
| Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents | Q37286620 | ||
| Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. | Q37319058 | ||
| Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters | Q37769761 | ||
| Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review | Q38003191 | ||
| Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice | Q38476603 | ||
| The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. | Q38896798 | ||
| Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. | Q39365345 | ||
| Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. | Q39673704 | ||
| The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets | Q40119975 | ||
| Discovery and validation of novel peptide agonists for G-protein-coupled receptors. | Q40455390 | ||
| Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. | Q40510688 | ||
| A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. | Q40853474 | ||
| Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury. | Q40867212 | ||
| The mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors | Q41653426 | ||
| Cellular carboxypeptidases | Q41745113 | ||
| An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect | Q41830683 | ||
| Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester | Q42039095 | ||
| Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). | Q42447014 | ||
| Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. | Q42521222 | ||
| Knockout of angiotensin 1-7 receptor Mas worsens the course of two-kidney, one-clip Goldblatt hypertension: roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II. | Q42821359 | ||
| Altered cardiovascular reflexes responses in conscious Angiotensin-(1-7) receptor Mas-knockout mice | Q42984627 | ||
| Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. | Q43071456 | ||
| Ablation of angiotensin (1-7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction | Q43090043 | ||
| Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). | Q43142623 | ||
| Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. | Q43201847 | ||
| Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7). | Q43247685 | ||
| Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. | Q43547068 | ||
| Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). | Q44201695 | ||
| Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats | Q44811232 | ||
| Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. | Q45151827 | ||
| Myocardial infarction increases ACE2 expression in rat and humans. | Q45238600 | ||
| Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats | Q46252912 | ||
| Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. | Q46352475 | ||
| Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. | Q46378620 | ||
| G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor | Q46421423 | ||
| Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects | Q46604608 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 79-85 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Pfluegers Archiv | Q1091689 |
| P1476 | title | ACE2, angiotensin-(1–7), and Mas: the other side of the coin | |
| P478 | volume | 465 |
| Q31171637 | Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy. |
| Q35178620 | An angiotensin-(1-7) peptidase in the kidney cortex, proximal tubules, and human HK-2 epithelial cells that is distinct from insulin-degrading enzyme |
| Q91703665 | Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q38206728 | Angiotensin II and vascular injury |
| Q55022988 | Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury. |
| Q90745532 | Angiotensin-(1-7) Receptor Mas Deficiency Does Not Exacerbate Cardiac Atrophy Following High-Level Spinal Cord Injury in Mice |
| Q61449216 | Angiotensin-(1-7) Receptor Mas in Hemodynamic and Thermoregulatory Dysfunction After High-Level Spinal Cord Injury in Mice: A Pilot Study |
| Q52354923 | Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis. |
| Q35883490 | Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. |
| Q38207841 | Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets |
| Q33627982 | Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration |
| Q34558461 | Changes in levels of angiotensin II and its receptors in a model of inverted stress-induced cardiomyopathy |
| Q34275725 | Chronic treatment with Ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes |
| Q37592161 | Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems |
| Q47143424 | Comparative effects of angiotensin II and angiotensin-(4-8) on blood pressure and ANP secretion in rats |
| Q97084266 | Considerations for people with diabetes during the Coronavirus Disease (COVID-19) Pandemic |
| Q41652967 | Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis |
| Q35776021 | Early Training-Induced Reduction of Angiotensinogen in Autonomic Areas-The Main Effect of Exercise on Brain Renin-Angiotensin System in Hypertensive Rats |
| Q28085007 | Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension |
| Q42173694 | Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway |
| Q40603698 | Local expression of AP/AngIV/IRAP and effect of AngIV on glucose-induced epithelial transport in human jejunal mucosa |
| Q41015495 | Many Faces of Renin-angiotensin System - Focus on Eye. |
| Q88601204 | Modification of gene expression profiling related to renin-angiotensin system in an ischemia/reperfusion rat model after T3 infusion |
| Q37347190 | New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option? |
| Q38170474 | Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. |
| Q37081415 | Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure |
| Q38287148 | Salt feedback on the renin-angiotensin-aldosterone system |
| Q39134595 | Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. |
| Q38214892 | Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. |
| Q38168046 | The effect of RAAS blockade on the progression of diabetic nephropathy |
| Q98182389 | The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19) |
| Q64101852 | The renin-angiotensin-aldosterone system and its suppression |
Search more.